Long-term Treatment of Chronic Myeloid Leukemia

被引：3
作者：
Yavuz, Akif Selim [1 ]
机构：
[1] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Hematol, TR-34390 Istanbul, Turkey
来源：
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI | 2011年 / 21卷 / 02期
关键词：
Chronic myeloid leukemia; Long term treatment; Monitorization; CHRONIC MYELOGENOUS LEUKEMIA; PATIENTS RECEIVING IMATINIB; TYROSINE KINASE INHIBITORS; BCR-ABL TRANSCRIPTS; CHRONIC-PHASE; PHILADELPHIA-CHROMOSOME; MOLECULAR RESPONSES; INTERFERON-ALPHA; T-LYMPHOCYTES; FOLLOW-UP;
D O I：
10.4999/uhod.11013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Imatinib, a selective tyrosine kinases inhibitor (TKI), has excellent efficacy in the treatment of chronic myeloid leukemia (CML). Imatinib resistance and intolerance opened the way to the development of second generation TKIs against CML, including nilotinib and dasatinib. Because all TKIs are more effective drugs in comparison with previous therapies in CML, the follow-up period is now longer in the TKI era. These compounds are prescribed for prolonged periods, often in patients with comorbidities. Therefore, monitoring of CML should comprise the response to TKIs and long term effects of the TKIs.
引用
收藏
页码：10 / 17
页数：8
相关论文
共 55 条
[1]  
[Anonymous], 2003, Adherence to Long-Term Therapies: Evidence for action
[2]  
[Anonymous], 2007, TAS NIL NIL PRESCR I
[3]  
[Anonymous], 2007, SPRYC DAS DAS PRESCR
[4]  
[Anonymous], NCCN CHRON MYEL LEUK
[5]   Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate [J].
Arora, B ;
Kumar, L ;
Sharma, A ;
Wadhwa, J ;
Kochupillai, V .
ANNALS OF ONCOLOGY, 2004, 15 (02) :358-359
[6]   Congestive heart failure is a rare event in patients receiving imatinib therapy [J].
Atallah, Ehab ;
Durand, Jean-Bernard ;
Kantarjian, Hagop ;
Cortes, Jorge .
BLOOD, 2007, 110 (04) :1233-1237
[7]   Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].
Baccarani, Michele ;
Saglio, Giuseppe ;
Goldman, John ;
Hochhaus, Andreas ;
Simonsson, Bengt ;
Appelbaum, Frederick ;
Apperley, Jane ;
Cervantes, Francisco ;
Cortes, Jorge ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Frangois ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Niederwieser, Dielger ;
Silver, Richard ;
Hehlmann, Rudiger .
BLOOD, 2006, 108 (06) :1809-1820
[8]   Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].
Baccarani, Michele ;
Cortes, Jorge ;
Pane, Fabrizio ;
Niederwieser, Dietger ;
Saglio, Giuseppe ;
Apperley, Jane ;
Cervantes, Francisco ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Radich, Jerald ;
Simonsson, Bengt ;
Silver, Richard T. ;
Goldman, John ;
Hehlmann, Rudiger .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051
[9]   Altered bone and mineral metabolism in patients receiving imatinib mesylate [J].
Berman, E ;
Nicolaides, M ;
Maki, RG ;
Fleisher, M ;
Chanel, S ;
Scheu, K ;
Wilson, BA ;
Heller, G ;
Sauter, NP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) :2006-2013
[10]   The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro [J].
Blake, Stephen ;
Hughes, Timothy P. ;
Mayrhofer, Graham ;
Lyons, A. Bruce .
CLINICAL IMMUNOLOGY, 2008, 127 (03) :330-339
123456